Novel THPO variant in hereditary thrombocytopenia: A potential candidate variant for predisposition to myeloid neoplasm

PLoS One. 2022 Dec 19;17(12):e0271624. doi: 10.1371/journal.pone.0271624. eCollection 2022.

Abstract

Hereditary thrombocytopenia is a heterogeneous group of congenital disorders with a wide range of symptoms depending on the severity of platelet dysfunction or thrombocytopenia. Because of its clinical phenotypes and the bone marrow morphology associated with this condition, hereditary thrombocytopenia can be misdiagnosed as primary immune thrombocytopenia and myelodysplastic syndrome. Therefore, genetic evidence is necessary for the accurate diagnosis of hereditary thrombocytopenia. Refractory cytopenia of childhood is a subgroup of myelodysplastic syndrome that was added to the World Health Organization classification in 2008. To investigate the germline and somatic variants associated with refractory cytopenia of childhood, we performed targeted multigene sequencing in three patients with refractory cytopenia of childhood. Of the three patients, one progressed from megakaryocytic hypoplasia with thrombocytopenia, and targeted multigene sequencing revealed THPO variants in this patient and his sister. We propose that the monoallelic deletion of THPO is a potential candidate for germline predisposition to myeloid malignancy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Disease Susceptibility
  • Humans
  • Myelodysplastic Syndromes* / genetics
  • Myeloproliferative Disorders* / diagnosis
  • Neoplasms*
  • Thrombocytopenia* / diagnosis

Substances

  • 4,5,6,7-tetrahydroisoxazolo(4,5-c)pyridin-3-ol

Grants and funding

This work was supported by a National Research Foundation of Korea grant funded by the Korean government (MSIT) (NRF-2017R1A2A1A17069780, NRF-2020R1A3B3079653). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.